Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19
Sakin, Yusuf Serdar
Yalçın, Kadir Serkan
MetadataShow full item record
CitationYozgat, A., Kasapoglu, B., Can, G., Tanoglu, A., Sakin, Y. S., Yalcin, K. S., Gurler, M., Kaplan, M., Kaban, M. G., Kirsoy, M., Kara, U., & Kekilli, M. (2021). Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turkish Journal of Medical Sciences, 51(4), 1675–1681. https://doi.org/10.3906/sag-2103-80
Background and aim: The aim of this study is to evaluate whether the long-term (?4 weeks) use of proton pump inhibitors (PPIs) is arisk factor for intubation requirement and mortality in patients hospitalized for COVID-19.Materials and methods: In this multicentric retrospective study, a total of 382 adult patients (?18 years of age) with confirmedCOVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periodsduring which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included thosewho have used PPIs for more than 4 weeks.Results: The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did notuse any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026–1.068),current smoking (HR: 2.590, 95% CI: 1.334–5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06–2.41) were foundto be independent risk factors for mortality.Conclusion: The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes forpatients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19treatment.